Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Total Valuation
Abeona Therapeutics has a market cap or net worth of $274.98M. The enterprise value is $221.51M.
Market Cap$274.98M
Enterprise Value$221.51M
Share Statistics
Abeona Therapeutics has 57,049,023 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,049,023
Owned by Insiders7.20%
Owned by Institutions45.04%
Financial Efficiency
Abeona Therapeutics’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is -43.98%.
Return on Equity (ROE)0.45
Return on Assets (ROA)0.32
Return on Invested Capital (ROIC)-43.98%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee42.79K
Profits Per Employee523.40K
Employee Count136
Asset Turnover0.03
Inventory Turnover0.28
Valuation Ratios
The current PE Ratio of Abeona Therapeutics is 3.9. Abeona Therapeutics’s PEG ratio is -0.02.
PE Ratio3.9
PS Ratio47.95
PB Ratio1.75
Price to Fair Value1.75
Price to FCF-3.31
Price to Operating Cash Flow-3.34
PEG Ratio-0.02
Income Statement
In the last 12 months, Abeona Therapeutics had revenue of 5.82M and earned 71.18M in profits. Earnings per share was 1.34.
Revenue5.82M
Gross Profit4.29M
Operating Income-89.45M
Pretax Income71.28M
Net Income71.18M
EBITDA-85.89M
Earnings Per Share (EPS)1.34
Cash Flow
In the last 12 months, operating cash flow was -76.33M and capital expenditures -7.97M, giving a free cash flow of -84.30M billion.
Operating Cash Flow-76.33M
Free Cash Flow-84.30M
Free Cash Flow per Share-1.48
Dividends & Yields
Abeona Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change6.64%
50-Day Moving Average4.93
200-Day Moving Average5.48
Relative Strength Index (RSI)54.03
Average Volume (3m)1.37M
Important Dates
Abeona Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateMar 17, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Abeona Therapeutics as a current ratio of 6.93, with Debt / Equity ratio of 15.68%
Current Ratio6.93
Quick Ratio6.74
Debt to Market Cap0.07
Net Debt to EBITDA0.62
Interest Coverage Ratio-23.92
Taxes
In the past 12 months, Abeona Therapeutics has paid 100.00K in taxes.
Income Tax100.00K
Effective Tax Rate<0.01
Enterprise Valuation
Abeona Therapeutics EV to EBITDA ratio is -2.63, with an EV/FCF ratio of -2.68.
EV to Sales38.76
EV to EBITDA-2.63
EV to Free Cash Flow-2.68
EV to Operating Cash Flow-2.96
Balance Sheet
Abeona Therapeutics has $191.40M in cash and marketable securities with $24.97M in debt, giving a net cash position of $166.44M billion.
Cash & Marketable Securities$191.40M
Total Debt$24.97M
Net Cash$166.44M
Net Cash Per Share$2.92
Tangible Book Value Per Share$3.01
Margins
Gross margin is 26.32%, with operating margin of -1536.91%, and net profit margin of 1223.08%.
Gross Margin26.32%
Operating Margin-1536.91%
Pretax Margin1224.79%
Net Profit Margin1223.08%
EBITDA Margin-1475.69%
EBIT Margin-1536.91%
Analyst Forecast
The average price target for Abeona Therapeutics is $21.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.40
Price Target Upside343.98% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―